《美股业绩》辉瑞药厂季度少赚7%胜预期 下调全年收入预测上限
美国药厂辉瑞公布第三季度业绩。季度纯利21.94亿美元,按年跌71%。每股季度摊薄纯利39美仙,经调整後为每股72美仙,略高於市场预期的71美仙。季度收入121.31亿美元,按年跌4%。公司去年同期录得消费者保健业务出售收益80.87亿美元。
公司预计全年度收入介乎488亿至495亿美元,早前预测为介乎486亿至506亿美元。每股经调整年度摊薄纯利介乎2.88至2.93美元,早前预测为介乎2.85至2.95美元。
辉瑞股价昨日(27日)跌1.3%,报37.43美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.